M&A Deal Summary

Allergan Acquires Inamed

On March 23, 2006, Allergan acquired medical products company Inamed for 3.3B USD

Acquisition Highlights
  • This is Allergan’s 1st transaction in the Medical Products sector.
  • This is Allergan’s largest (disclosed) transaction.
  • This is Allergan’s 2nd transaction in the United States.
  • This is Allergan’s 2nd transaction in California.

M&A Deal Summary
Date 2006-03-23
Target Inamed
Sector Medical Products
Buyer(s) Allergan
Deal Type Add-on Acquisition
Deal Value 3.3B USD

Target

Inamed

Santa Barbara, California, United States
website
Inamed Corp. manufactures and develops healthcare products in US.

Search 192,723 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Allergan

Irvine, California, United States
Category Company
Founded 1948
Sector Life Science
Employees11,400
DESCRIPTION

Allergan, Inc. is a pharmaceutical company. Allergan's products include ophthalmic pharmaceuticals, dermatology products, and neurological products.

DEAL STATS #
Overall 2 of 14
Sector (Medical Products) 1 of 6
Type (Add-on Acquisition) 2 of 13
State (California) 2 of 8
Country (United States) 2 of 14
Year (2006) 1 of 1
Size (of disclosed) 1 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2003-11-20 Oculex Pharmaceuticals

Sunnyvale, California, United States

Oculex Pharmaceuticals, Inc. is an Ophthalmic drug delivery company.

Buy $230M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-09-19 Esprit Pharma

Irvine, California, United States

Esprit is a U.S.-based pharmaceutical company focused on the genitourinary (GU) and women’s healthcare markets. Esprit currently markets SANCTURA® (trospium chloride) for the treatment of overactive bladder (OAB), as well as ESTRASORB® (estradiol topical emulsion) for vaso-motor symptoms associated with menopause. In addition, Esprit controls marketing rights to the recently approved SANCTURA® XR, a novel, once-daily formulation of trospium chloride that has demonstrated outstanding clinical results in terms of efficacy and tolerability in the treatment of OAB.

Buy -
Mergr

Product

Company

Legal